FDA Approves Ocrevus for Children With Relapsing-Remitting Multiple Sclerosis

The U.S. Food and Drug Administration has approved Ocrevus for children ages 10 and older with relapsing-remitting multiple sclerosis, making it only the second therapy cleared for pediatric patients in the United States. The decision gives families a new high-efficacy option that may dramatically slow disease progression in young patients.

Multiple sclerosis is rare in children, but when it occurs it almost always takes the relapsing-remitting form, marked by sudden symptom flares followed by periods of recovery. The approval was based on the Phase 3 clinical trial OPERETTA 2, which enrolled 187 children and adolescents. Results showed that patients receiving Ocrevus had a 48 percent lower risk of relapse compared with those taking the only other approved pediatric therapy, Gilenya. The treatment also reduced the number of patients with new or enlarging brain lesions by 48 percent and lowered those with actively inflamed lesions by 87 percent.

Ocrevus works by depleting B-cells, immune cells that drive the inflammation damaging nerves in the brain and spinal cord. It is given as an intravenous infusion, with the first two doses two weeks apart and subsequent doses every six months. The safety profile in children matched what has been seen in adults, and no patients in the Ocrevus group stopped treatment due to side effects. The therapy was already approved for adults with relapsing forms of MS and primary progressive MS.

What This Means for Young Patients and Families

Pediatric-onset MS affects an estimated 5,000 to 10,000 children and adolescents in the U.S. Until now, only one daily oral medication was available for them. Advocates say the approval changes the landscape for families who have long struggled with limited options. Emily Blosberg, who was diagnosed with MS as a teenager and later founded the nonprofit Mr. Oscar Monkey, called the decision a “game changer.” She noted that the next generation of patients “won’t have to wait for answers” and can potentially stop relapses and brain lesions before they cause lasting harm.

The approval opens the door for earlier, more aggressive treatment in children, which experts believe could alter the long-term course of the disease. With a decade of safety and efficacy data now supporting its use in younger patients, Ocrevus offers a new path forward for families navigating a diagnosis that is both rare and daunting. Researchers continue to monitor long-term outcomes, but for now, the decision brings a sense of hope to a community that has often had to wait.